Literature DB >> 26049739

Retrograde puncture assisted hepatic vein recanalization in treating Budd-Chiari syndrome with segmental obstruction of hepatic vein.

Yan-Feng Cui1, Yu-Fei Fu2, Ning Wei1, Hong-Chao Zhu1, Hao Xu3.   

Abstract

PURPOSE: This study aimed at investigating the feasibility and effectiveness of retrograde puncture assisted hepatic vein (HV) recanalization in management of Budd-Chiari syndrome (BCS) patients with segmental obstruction of HV.
MATERIALS AND METHODS: From May 2011 to August 2014, 76 BCS patients with obstruction of HV were treated by routine transjugular HV recanalization in our center. Among them, 17 patients with segmental obstruction (obstruction length >1 cm) of HV experienced failure of the routine transjugular HV recanalization and underwent retrograde puncture assisted HV recanalization. Data on technical success, clinical success and follow-up were collected and analyzed retrospectively.
RESULTS: Retrograde puncture assisted HV recanalization was technically successful in 14 of 17 (82 %) patients. Of these 14 patients, 12 patients underwent HV balloon dilation, and 2 patients underwent HV stent insertion. No procedure-related complications occurred in any of our patient. Clinical success was achieved in all of the 14 patients who experienced technical success. The mean HV pressure decreased from 43.6 ± 6.7 cmH2O before treatment to 18.4 ± 4.8 cmH2O after treatment (P < 0.001). BCS-related symptoms began to improve on the next day following the treatment. During 4-43 months (mean 17.4 ± 10.8 months) of follow-up, three patients experienced re-obstruction of HV.
CONCLUSIONS: Retrograde puncture assisted HV recanalization is a simple, safe, and effective treatment for BCS patients with segmental obstruction of HV. It can serve as an additional treatment option for patients who experience the technical failure of routine transjugular HV recanalization.

Entities:  

Keywords:  Budd–Chiari syndrome; Hepatic vein; Retrograde puncture

Mesh:

Year:  2015        PMID: 26049739     DOI: 10.1007/s11547-015-0557-6

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  9 in total

1.  Treatment of Budd-Chiari syndrome with urokinase following predilation in patients with old inferior vena cava thrombosis.

Authors:  P-X Ding; Y-D Li; X-W Han; G Wu; S-F Shui; Y-L Wang
Journal:  Radiol Med       Date:  2010-10-06       Impact factor: 3.469

2.  Recanalization of occlusive transjugular intrahepatic portosystemic shunts inaccessible to the standard transvenous approach.

Authors:  Roberto Miraglia; Luigi Maruzzelli; Angelo Luca
Journal:  Diagn Interv Radiol       Date:  2012-06-22       Impact factor: 2.630

3.  Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome.

Authors:  C E Eapen; D Velissaris; M Heydtmann; B Gunson; S Olliff; E Elias
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

Review 4.  Interventional radiology in the management of Budd Chiari syndrome.

Authors:  David Beckett; Simon Olliff
Journal:  Cardiovasc Intervent Radiol       Date:  2008-01-23       Impact factor: 2.740

5.  Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center.

Authors:  Guohong Han; Xingshun Qi; Wei Zhang; Chuangye He; Zhanxin Yin; Jianhong Wang; Jielai Xia; Ke Xu; Wengang Guo; Jing Niu; Kaichun Wu; Daiming Fan
Journal:  Radiology       Date:  2012-11-09       Impact factor: 11.105

6.  Applicability of different endovascular methods for treatment of refractory Budd-Chiari syndrome.

Authors:  Yong Gao; Shiyuan Chen; Chaowen Yu
Journal:  Cell Biochem Biophys       Date:  2011-11       Impact factor: 2.194

7.  Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites.

Authors:  Ahmad Parvinian; James T Bui; M Grace Knuttinen; Jeet Minocha; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

8.  Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome.

Authors:  Chun-Qing Zhang; Li-Na Fu; Lin Xu; Guo-Quan Zhang; Tao Jia; Ji-Yong Liu; Cheng-Yong Qin; Ju-Ren Zhu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

9.  Catheter-directed thrombolytic therapy combined with angioplasty for hepatic vein obstruction in Budd-Chiari syndrome complicated by thrombosis.

Authors:  Qingqiao Zhang; Hao Xu; Maoheng Zu; Yuming Gu; Ning Wei; Wenliang Wang; Zhikang Gao; Bin Shen
Journal:  Exp Ther Med       Date:  2013-07-30       Impact factor: 2.447

  9 in total
  5 in total

1.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

2.  Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival.

Authors:  Yan-Feng Cui; Yu-Fei Fu; De-Chun Li; Hao Xu
Journal:  Hepatol Int       Date:  2015-10-23       Impact factor: 6.047

3.  Outcomes of endovascular interventional therapy for primary Budd-Chiari syndrome caused by hepatic venous obstruction.

Authors:  De-Lei Cheng; Nan Zhu; Hao Xu; Cheng-Li Li; Wei-Fu Lv; Wei-Wei Fang; Chuan-Ting Li
Journal:  Exp Ther Med       Date:  2018-09-07       Impact factor: 2.447

4.  Evaluation of outcome from endovascular therapy for Budd-Chiari syndrome: a systematic review and meta-analysis.

Authors:  Gauri Mukhiya; Xueliang Zhou; Xinwei Han; Dechao Jiao; Gaurab Pokhrel; Yahua Li; Sita Pokhrel
Journal:  Sci Rep       Date:  2022-09-28       Impact factor: 4.996

5.  Management of portal hypertension derived from uncommon causes.

Authors:  Sung Hyun Kim; Hae Min Lee; Seung Ho Lee; Jong Yoon Won; Kyung Sik Kim
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2016-05-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.